L Number	Hits	Search Text	DB	Time stamp
1	3903	("514/183,430,456").CCLS	USPAT	2004/01/31 13:23
2	1618	("549/23,362,396,406,407").CCLS	USPAT	2004/01/31 13:23
3	427	(("514/183,430,456").CCLS) and (("549/23,362,396,406,407").CCLS)	USPAT	2004/01/31 13:24
4	37	((("514/183,430,456").CCLS) and (("549/23,362,396,406,407").CCLS)) and chromene	USPAT	2004/01/31 13:24
5	21	((((("514/183,430,456").CCLS) and (("549/23,362,396,406,407").CCLS)) and chromene) and oxo	USPAT	2004/01/31 13:24

AN 1998:269548 CAPLUS
DN 128:265746
TI (R)-(+)-2-[[[3-(Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine Methanesulfonate: A New Selective Rat 5-Hydroxytryptamine1B Receptor Antagonist
AU Berg, Stefan; Larsson, Lars-Gunnar; Renyi, Lucy; Ross, Svante B.; Thorberg, Seth-Olof; Thorell-Svantesson, Gun
CS Departments of Medicinal Chemistry Behavioral and Biochemical Pharmacology and Molecular Pharmacology, Preclinical RD, Soedertaelje, S-151 85, Swed.
SO Journal of Medicinal Chemistry (1998), 41(11), 1934-1942
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



I

AB In the search for new 5-hydroxytryptamine (5-HT) receptor antagonists it was found that the compd. (R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine methanesulfonate [(R)-I.cntdot.MeSO3H.cntdot.H2O], is a selective rat 5-hydroxytryptamine1B (r5-HT1B) receptor antagonist. The binding profile showed a 6-fold preference for r5-HT1B (Ki = 47 .+-. 5 nM; n = 3) vs bovine 5-HT1B (Ki = 630 nM; n = 1) receptors. (R)-I.cntdot.MeSO3H.cntdot.H2O had very low affinity for other monoaminergic receptors examd. The r5-HT1B receptor antagonism was demonstrated by the potentiation of the K+-stimulated release of [3H]-5-HT from superfused rat brain slices in vitro, an effect that was antagonized by addn. of 5-HT to the superfusion fluid. (R)-I.cntdot.MeSO3H.cntdot.H2O at 20 mg/kg s.c. enhanced the 5-HT turnover in four rat brain regions (hypothalamus, hippocampus, striatum, and frontal cortex) with about 40% measured as the 5-HTP accumulation after decarboxylase inhibition with 3-hydroxybenzylhydrazine. At 3 mg/kg s.c. (R)-I.cntdot.MeSO3H.cntdot.H2O produced a significant increase in the no. of wet-dog shakes in rats, a 5-HT2A/5-HT2C response that was abolished by depletion of 5-HT after pretreatment with the tryptophan hydroxylase inhibitor p-chlorophenylalanine. These observations show that (R)-I.cntdot.MeSO3H.cntdot.H2O, by inhibiting terminal r5-HT1B autoreceptors, increases the 5-HT turnover and the synaptic concn. of 5-HT.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



I



II

AB The title compds. I [R1, R2 and R3 represent each lower alkoxy, etc., or R1 and R2 may be combined together to represent O(CH2)mO (wherein m is an integer of 1 - 3), etc.; R4 represents hydrogen, lower alkyl or aralkyl; R5 represents hydroxy, amino or lower alkoxy; R6 represents hydrogen or lower alkyl, or CR5R6 = carbonyl; dotted line indicates single or double bond; when dotted line indicates double bond, there is no R5; A represents an ethylene group which may be substituted by lower alkyl; and B represents optionally branched C1-C10 alkylene], useful for treating diseases such as anxiety, manic-depressive state and schizophrenia, sex disorder, eating disorder, sleep disorder, and drug dependence, are prepd. **Chromene** deriv. II hemifumarate (prepn. given) in vitro showed potent affinity for 5-HT 1A receptor with Ki of 0.159 nM.

ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:568450 CAPLUS

DN 122:314453

TI Preparation and formulation of chroman and **chromene** derivatives with selective affinity for **5HT** 1A receptors

IN Yasunaga, Tomoyuki; Kimura, Takenori; Naito, Ryo; Kontani, Toru; Yamaguchi, Tokio; Wanibuchi, Fumikazu

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9429293	A1	19941222	WO 1994-JP923	19940608
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			JP 1993-138580	19930610
AU 9469361	A1	19950103	AU 1994-69361	19940608
			JP 1993-138580	19930610
			WO 1994-JP923	19940608

OS MARPAT 122:314453

GI

Patel <1/31/2004>

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN
NEWS 20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus

NEWS EXPRESS	DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:29:44 ON 31 JAN 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:29:54 ON 31 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2004 HIGHEST RN 644468-14-4
DICTIONARY FILE UPDATES: 30 JAN 2004 HIGHEST RN 644468-14-4

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading 10051776.7

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,NH

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 12:30:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 32 TO ITERATE

100.0% PROCESSED 32 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'MARPAT' ENTERED AT 12:30:28 ON 31 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 140 ISS04)(20040123ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6667161 23 DEC 2003
DE 10317295 24 DEC 2003
EP 1371658 17 DEC 2003

JP 2003346928 05 DEC 2003
WO 2004000750 31 DEC 2003

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 12:30:34 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 2974 TO ITERATE

100.0% PROCESSED 2974 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.09

L3 5 SEA SSS FUL L1

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.42	265.05

FILE 'CAOLD' ENTERED AT 12:30:51 ON 31 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l2 sss full
L4 0 L2

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	265.47

FILE 'CAPLUS' ENTERED AT 12:31:05 ON 31 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 31 Jan 2004 VOL 140 ISS 6
FILE LAST UPDATED: 30 Jan 2004 (20040130/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L5 5 L3

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:539472 CAPLUS
DN **137:93772**
TI Preparation of piperazinylchromenones as 5-HT1B 5-HT1D agonists/antagonists useful as drugs.
IN Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055013	A2	20020718	WO 2002-SE69	20020115
	WO 2002055013	A3	20021114		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-262109PP	20010116
				SE 2001-3647 A	20011101
	EP 1353914	A2	20031022	EP 2002-729623	20020115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-262109PP	20010116
				SE 2001-3647 A	20011101
				WO 2002-SE69 W	20020115
	NO 2003003204	A	20030902	NO 2003-3204	20030715
				US 2001-262109PP	20010116
				SE 2001-3647 A	20011101
				WO 2002-SE69 W	20020115

OS MARPAT 137:93772
GI



—I —

AB Title compds. [I; R1 = H, thiomethoxy, NHA, NA2, NHCOA, halo, OH, OA, cyano, aryl, (substituted) alkyl, cycloalkyl, etc.; A = (substituted) alkyl, cycloalkyl, alkenyl, alkynyl; R2 = (substituted) piperazinyl, homopiperazinyl, aminoalkylamino, aminoheterocyclyl, heterocyclylamino; R6 = H, Me; Y = CONH, CONA, CSNH, CH2CO, CH2NA, piperazinylcarbonyl, 5-membered heterocyclylene, etc.; R7 = (substituted) mono- or bicyclic aryl, heterocyclyl], were prepd. Thus, 8-(4-methyl-1-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid hydrochloride (prepn. given) in DMF/Et3N was treated sequentially with 1-hydroxybenzotriazole, O-(1H-benzotriazol-1-yl)-N,N,N',N'-pentamethyleneuronium tetrafluoroborate, 4-dimethylaminopyridine, and 4-(4-morpholinyl)aniline (prepn. given) to give 8-(4-methyl-1-piperazinyl)-N-[4-(4-morpholinyl)phenyl]-4-oxo-4H-chromene-2-carboxamide. Several I showed 5-HT1B antagonist activity in the range 0.006-5.5 mg/kg in a screen for reversal of hypothermia in guinea pigs.

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:539471 CAPLUS
DN **137:109205**
TI Preparation of 4-oxo-4H-chromene-2-carboxamides and related compounds as antagonists or agonists of serotonin 5HT1B and 5HT1D receptors
IN Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002055012	A2	20020718	WO 2002-SE68	20020115
	WO 2002055012	A3	20021114		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-262107PP 20010116
SE 2001-3650 A 20011101
EP 1353913 A2 20031022 EP 2002-729622 20020115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2001-262107PP 20010116
SE 2001-3650 A 20011101
WO 2002-SE68 W 20020115
US 2003013708 A1 20030116 US 2002-51776 20020116
US 2001-262107PP 20010116
SE 2001-3650 A 20011101
WO 2002-SE68 W 20020115
NO 2003003203 A 20030902 NO 2003-3203 20030715
US 2001-262107PP 20010116
SE 2001-3650 A 20011101
WO 2002-SE68 W 20020115

OS MARPAT 137:109205

GI



I



II



III

AB Title compds. I and their pharmaceutically acceptable salts [R1 = H, alkyl, cycloalkyl, thiomethoxy, etc.; R2 = NR3R3; R3 independently = H, (un)substituted alkylamine e.g., alkyl, alkenyl, alkynyl amino-heterocycle, etc; R3-R3 = (un)substituted cycloalkylamine or amino-heterocycle e.g., alkyl, alkenyl, alkynyl, etc; R5 = H, O, S, etc.; R6 = H, Me; R7 = (un)substituted mono-. or bicylo- arom., (un)substituted heterocycle; X = O, N, NH, S; Y = CONH, NHCO, CSNH, etc.] were prepd with the proviso that multiple bonds are sepd. from each other by at least one

single bond. For example, condensation of 4-oxo-4H-chromene-2-carboxylic acid II e.g., prepd. from diethylacetylenedicarboxylate and 2-bromo-4-fluorophenol in 5 steps, and 4-morpholin-4-yl-phenylamine provided preferred 4-oxo-4H-chromene-2-carboxamide III. The utility of the compds. of the present invention were tested using a guinea pig hypothermia test, ED50 values for compds. I range from 0.006-5.5 mg/kg. Compds. I are disclosed to be antagonists or agonists of serotonin 5HT1B and 5HT1D receptors (no data provided). Also I are claimed for use in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, etc..

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:209909 CAPLUS
DN **132:241974**
TI Method for solubilizing pyridonecarboxylic acid, solubilizer therefor, aqueous solution preparations containing pyridonecarboxylic acid and process for producing the same
IN Sawa, Shirou
PA Senju Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000016774	A1	20000330	WO 1999-JP4992	19990913
W: CA, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			JP 1998-265523 A	19980918
CA 2310433	AA	20000330	CA 1999-2310433	19990913
			JP 1998-265523 A	19980918
			WO 1999-JP4992 W	19990913
EP 1044688	A1	20001018	EP 1999-943315	19990913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
			JP 1998-265523 A	19980918
			WO 1999-JP4992 W	19990913
US 6306856	B1	20011023	US 2000-554660	20000518
			JP 1998-265523 A	19980918
			WO 1999-JP4992 W	19990913

OS MARPAT 132:241974
AB A method for solubilizing pyridonecarboxylic acid or a pharmacol. acceptable salt thereof is characterized by blending glycyrrhizinic acid or its salt with pyridonecarboxylic acid or a pharmacol. acceptable salt thereof. Disclosed is an aq. soln. contg. the thus solubilized pyridonecarboxylic acid or a salts thereof. By using the above solubilization method, the soly. of a pyridonecarboxylic acid compd. or its salt can be elevated at around the physiol. pH value thereof, which makes it possible to prep. aq. soln. prepns. to be used mainly as eye drops, nasal drops, ear drops, etc. An ear drop soln. (pH 7.0) contained lomefloxacin.cntdot.HCl 0.3, dipotassium glycyrrhizinate 0.1, boric acid 1.6 g, NaOH q.s., HCl q.s, and distd. water q.s. to 100 mL.
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:527058 CAPLUS
DN **129:153244**
TI Method for stabilizing arylcarboxylic acids with heterocyclic bases
IN Sawa, Shirou
PA Senju Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 856310	A2	19980805	EP 1998-101804	19980203
	EP 856310	A3	20000119		
	EP 856310	B1	20031112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				JP 1997-21805 A	19970204
	US 6274592	B1	20010814	US 1998-17626	19980202
				JP 1997-21805 A	19970204
	CA 2228536	AA	19980804	CA 1998-2228536	19980203
				JP 1997-21805 A	19970204
	JP 10279503	A2	19981020	JP 1998-22363	19980203
				JP 1997-21805 A	19970204
	AT 253891	E	20031115	AT 1998-101804	19980203
				JP 1997-21805 A	19970204
	US 2001056098	A1	20011227	US 2001-885096	20010621
				JP 1997-21805 A	19970204
				US 1998-17626 A3	19980202

OS MARPAT 129:153244
GI



I

AB An antiinflammatory arylcarboxylic acid, e.g. pranoprofen, is stabilized in aq. soln. at all temps. by adding a heterocyclic base [I; A, A', X = C, N; Y, Z = C, or YZ = CH; R2-R8 = H, halo, CO2H, (substituted) alkyl, (substituted) cycloalkyl, (substituted) acyl, (substituted) aryl, (substituted) heterocycle; R4R5 and R6R7 may complete heterocyclic rings]. Such aq. solns. can be used as eye drops, nasal drops, ear drops, etc. Thus, an aq. soln. contg. pranoprofen 0.5 and H3BO3 1.6 wt.% was stabilized during storage at 4, 60, and 80.degree. for 1-4 wk by addn. of 0.3 wt.% caffeine.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:748455 CAPLUS

DN **126:31277**
TI Quinoline derivatives useful as endothelin receptor antagonists, process for their preparation, the resultant intermediates, their use as medicaments, and pharmaceutical compositions containing them
IN Hawsslein, Jean-Luc
PA Roussel-UCLAF, Fr.; Haesslein, Jean-Luc
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9633190	A1	19961024	WO 1996-FR591	19960418
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				FR 1995-4722	19950420
	FR 2733233	A1	19961025	FR 1995-4722	19950420
	FR 2733233	B1	19970530		

OS MARPAT 126:31277
GI



I



II



III

AB The invention concerns compds. I and their isomers and addn. salts [wherein A = H or CH2B; B = alkyl, C6H3R1R2R3, (un)substituted 3-pyridyl, cyclohexyl, or 2-furyl; Z1, Z2 = H, or together form fused carbo- or heterocyclic (O, S, N, NH) ring; Z = O or S; X = CO2H or derivs.,

tetrazolyl, CONHSO2R6; R6 = (un)substituted alkyl, alkenyl or Ph; R = H, halo, OH, SH, CO2H, alkyl, phenylthioalkyl, alkoxy, Ph, naphthyl, PhCH2, PhCH2CH2, various heterocycles, and PhS, most of which may be substituted; R1-R5 = H, halo, OH, alkyl, alkoxy, cyano, NO2, etc.; or R2R3 may likewise form the rings formed by Z1 and Z2, with the proviso that when A = H, then Z1Z2 form ring]. I are endothelin receptor antagonists, useful for treatment of vascular spasms, renal insufficiency, atherosclerosis, hypertension, asthma, osteoporosis, etc. For example, the intermediate II (prepn. given) underwent a sequence of condensation with aniline, thermal cyclization to a dihydroquinolone, N-alkylation with piperonyl bromide, and hydrolysis with aq. ethanolic KOH, to give title potassium salt III. In tests for inhibition of endothelin receptors A and B in vitro, III had IC50 values of 10.6 nM and 606 nM, resp.

```
=> s chromene and5HT
L6            0 CHROMENE AND5HT

=> s chromene and 5HT
L7            5 CHROMENE AND 5HT

=> d l7 fbib hitstr abs total

L7   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:356424  CAPLUS
DN   138:368765
TI   Preparation of 4-oxo-4H-chromene-2-carboxamides and
     4-oxo-1,4-dihydroquinoline-2-carboxamides as 5-HT antagonists for
     treatment of psychiatric disorders
IN   Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler,
     Carey; McCauley, John; Pierson, Edward; Sohn, Daniel
PA   Astrazeneca AB, Swed.
SO   PCT Int. Appl., 160 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.   DATE
     ---------------    ----  --------      ---------------   --------
PI   WO 2003037872      A1    20030508      WO 2002-SE1989    20021101
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
                                           SE 2001-3649    A 20011101
OS   MARPAT 138:368765
GI
```



I



II

AB Quinolines I [wherein R1 = independently H, halo, OH, CN, MeO, MeS, NHA, NA2, NHCOA, CONH2, CONHA, CONA2, OA, aryl, or (un)substituted (cyclo)alkyl; R2 = NR3(CH2)nN(R3)2, QN(R3)2, NR3QR3, or (un)substituted piperazinyl, homopiperazinyl, or 1,4-diazacyclooctyl; R3 = H, AOH, or (un)substituted (cyclo)alkyl, alkenyl, or alkynyl; R4 = H or (un)substituted alkyl; R5 = O, OR4, N(R4)2 or SR4; R6 = H or Me; R7 = (un)substituted aryl or heterocyclyl; R8 = CH2, CO, SO2, SO2NH, CONH, O, S, SO, or heterocyclyl connected to R7 by a ring fusion or single bond; A = (un)substituted (cyclo)alkyl, alkenyl, or alkynyl; Q = heterocyclyl; Y = CONH, CONA, NHCO, CSNH, CH2NH, COCH2, CH2CO, CO-piperazinediyl, COR8, NACO, CSNA, CH2NA, NACH2, or 5-membered heterocyclyl] are disclosed as 5-HT1B and 5-HT1D antagonists. Related 4-oxo-4H-**chromene**-2-carboxamides and 4-oxo-1,4-dihydroquinoline-2-carboxamides were prepd. and tested for biol. activity. For example, reaction of di-Et acetylenedicarboxylate with 2-bromophenol in the presence of a catalytic amt. of tetrabutylammonium fluoride afforded 2-(2-bromophenoxy)but-2-enedioic acid di-Et ester (91%), which was sapond. with NaOH to give the diacid (88%). Cyclization using H2SO4 in EtOH provided Et 8-bromo-4-oxo-4H-**chromene**-2-carboxylate (24%). Pd-catalyzed substitution with N-methylpiperazine (70%), conversion to the HCl salt of the acid (100%), and amidation with 4-(4-morpholinyl)aniline in the presence of HOBt and TBTU in DMF and TEA gave II. All example compds. showed affinity for 5-HT1B and 5-HT1D receptors with Ki values of < 10 .mu.M. II was among twelve example compds. which reversed 5-HT1B agonist-induced hypothermia in guinea pigs in a dosage range of 0.006 mg/kg - 5.5 mg/kg. In addn., four chromenones demonstrated activity in a learned helplessness assay for antidepressant/antianxiety activity. I are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders (no data). The compds. may also be useful in the treatment of gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm, and sexual dysfunction (no data).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:356423 CAPLUS
DN 138:368764
TI Preparation of 4-oxo-4H-**chromene**-2-carboxamides and 4-oxo-1,4-dihydroquinoline-2-carboxamides as 5-HT antagonists for treatment of psychiatric disorders
IN Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; Pierson, Edward; Sohn, Daniel; McCauley, John
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003037871	A1	20030508	WO 2002-SE1987	20021101

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

SE 2001-3648 A 20011101

OS MARPAT 138:368764
GI



I



II

AB Title quinolinones I [wherein R1 = H, halo, OH, CN, MeO, MeS, NHA, NA2, NHCOA, CONH2, CONHA, CONA2, OA, aryl, or (un)substituted (cyclo)alkyl; R2 = NR3(CH2)nN(R3)2, QN(R3)2, NR3QR3, or (un)substituted piperazinyl, homopiperazinyl, or 1,4-diazacyclooctyl; R3 = H, AOH, or (un)substituted (cyclo)alkyl, alkenyl, or alkynyl; R4 = H or (un)substituted alkyl; R5 = O, NR4, or S; R6 = H or Me; R7 = (un)substituted aryl or heterocyclyl; R8 = CH2, CO, SO2, SO2NH, CONH, O, S, SO, or heterocyclyl connected to R7 by a ring fusion or single bond; A = (un)substituted (cyclo)alkyl, alkenyl, or alkynyl; Q = heterocyclyl; Y = CONH, CONA, NHCO, CSNH, CH2NH, COCH2, CH2CO, CO-piperazinediyl, COR8, NACO, CSNA, CH2NA, NACH2, or 5-membered heterocyclyl] and related chromenones were prepd. as 5-HT1B and 5-HT1D antagonists. For example, reaction of di-Et acetylenedicarboxylate with 2-bromophenol in the presence of a catalytic amt. of tetrabutylammonium fluoride afforded 2-(2-bromophenoxy)but-2-enedioic acid di-Et ester (91%), which was sapond. with NaOH to give the diacid (88%). Cyclization using H2SO4 in EtOH provided Et 8-bromo-4-oxo-4H-**chromene** -2-carboxylate (24%). Pd-catalyzed substitution with N-methylpiperazine (70%), conversion to the HCl salt of the acid (100%), and amidation with 4-(4-morpholinyl)aniline in the presence of HOBt and TBTU in DMF and TEA gave II. All example compds. showed affinity for 5-HT1B and 5-HT1D receptors with Ki values of < 10 .mu.M. II was among twelve example compds. which reversed 5-HT1B agonist-induced hypothermia in guinea pigs in a dosage range of 0.006 mg/kg - 5.5 mg/kg. In addn., four chromenones demonstrated activity in a learned helplessness assay for antidepressant/antianxiety activity. Thus, I are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders (no data). The compds. may also be useful in the treatment of gastrointestinal disorders, motor disorders, endocrine disorders, vasospasm, and sexual dysfunction (no data).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:693264 CAPLUS
DN 135:257269
TI Preparation of N-heterocyclyl amide compounds as 5-HT antagonists
IN Yamada, Akira; Tomishima, Masaki; Hayashida, Hisashi; Imanishi, Masashi; Spears, Glen W.; Ito, Kiyotaka; Takahashi, Fumie; Miyake, Hiroshi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 239 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001068585	A1	20010920	WO 2001-JP1993	20010313
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
			JP 2000-70127 A	20000314
			JP 2000-305947 A	20001005
AU 2001041128	A5	20010924	AU 2001-41128	20010313
			JP 2000-70127 A	20000314
			JP 2000-305947 A	20001005
			WO 2001-JP1993 W	20010313
EP 1264820	A1	20021211	EP 2001-912338	20010313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			JP 2000-70127 A	20000314
			JP 2000-305947 A	20001005
			WO 2001-JP1993 W	20010313

OS CASREACT 135:257269; MARPAT 135:257269
AB Amides compds. represented by the general formula R1-A-X-NHCO-Y-R2 [wherein R1 is an optionally substituted heterocyclic group or optionally substituted phenyl; R2 is optionally substituted fused Ph, optionally substituted Ph, or optionally substituted thienyl; A is a group represented by the formula -(CH2)t-(O)m- or -(CR3R4)pNR5(CO)n- (wherein R3 and R4 each is hydrogen or R3 and R4 in combination form imino; R5 is hydrogen or lower alkyl; t is 0, 1, or 2; and p, m, and n each is 0 or 1); X is optionally substituted phenylene or an optionally substituted, divalent, nitrogenous heterocyclic group; and Y is a bond, lower alkylene, or lower alkenylene] and salts thereof are prepd. Theses amides include phenylacetamide, cinnamides, 1H-indole-7-carboxamides, 3-(2-pyridyl)-2-propenamides, 5-phenyl-2-thiophenecarboxamides, 9H-carbazolecarboxamides, 3-phenyl-2-propenamides, 9H-fluorene-1-carboxamides, 2,3-dihydrobenz[b]oxepine-4-carboxamides, 1H-benzo[b]thiepin-4-carboxamides, and 3-(1H-indol-3-yl)-2-propenamides. They are antagonists of 5-hydroxytryptamine (5-HT), in particular 5-HT2c, and are useful for the treatment of 5-HT-mediated diseases such as (1) central nervous system disorders in including anxiety, depression, obsessive-compulsive neurosis, migraine headache, anorexia, Alzheimer's disease, sleep disorder, over-eating, and panic, (2) withdrawal symptom